31 results on '"Sabo JP"'
Search Results
2. Pharmacokinetic Interaction between Faldaprevir and Cyclosporine or Tacrolimus in Healthy Volunteers: A Prospective, Open-Label, Fixed-Sequence, Crossover Study.
- Author
-
Huang F, Voelk C, Trampisch M, Rowland L, Schultz A, and Sabo JP
- Subjects
- Adolescent, Adult, Aminoisobutyric Acids, Antiviral Agents therapeutic use, Area Under Curve, Cross-Over Studies, Cyclosporine therapeutic use, Drug Interactions, Female, Graft Rejection prevention & control, Healthy Volunteers, Hepatitis C prevention & control, Humans, Leucine analogs & derivatives, Liver Transplantation adverse effects, Male, Middle Aged, Oligopeptides therapeutic use, Proline analogs & derivatives, Prospective Studies, Quinolines, Secondary Prevention methods, Tacrolimus therapeutic use, Thiazoles therapeutic use, Young Adult, Antiviral Agents pharmacokinetics, Cyclosporine pharmacokinetics, Immunosuppressive Agents pharmacokinetics, Oligopeptides pharmacokinetics, Tacrolimus pharmacokinetics, Thiazoles pharmacokinetics
- Abstract
Faldaprevir (FDV) is a potent, orally administered inhibitor of hepatitis C virus. In this single-centre, open-label, fixed-sequence, crossover study of 32 healthy adult male and female volunteers, subjects received either a single dose of cyclosporine (CsA) 50 mg (N = 16) or tacrolimus (TAC) 0.5 mg (N = 16), followed by a washout of at least 14 days. Each subject then received a loading dose of FDV 240 mg followed by 120 mg FDV once daily for 6 days. FDV 120 mg was then co-administered with an additional single dose of CsA (50 mg) or TAC (0.5 mg), followed by an additional 6 days of FDV 120 mg once daily. Intensive blood sampling was performed to assess the PK interaction potential. Assessment of relative BA indicated that exposure to CsA co-administered with FDV was similar to CsA alone. However, the AUC
τ,ss and Cmax,ss of FDV were increased by 23% and 41%, respectively, when FDV was co-administered with CsA. Exposure to TAC was slightly increased (AUC0-∞ increased by 27%, no change in Cmax ) when TAC was co-administered with FDV. In contrast, exposure to FDV co-administered with TAC was similar to FDV alone. No unexpected safety findings arose from the trial. The limitations of the study (use of single, low dose of TAC and CsA, and only healthy volunteers in the trial) are discussed., (© 2018 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society).)- Published
- 2018
- Full Text
- View/download PDF
3. Pharmacokinetic analysis of nevirapine extended release 400 mg once daily vs nevirapine immediate release 200 mg twice daily formulation in treatment-naïve patients with HIV-1 infection.
- Author
-
Yong CL, Gathe JC, Knecht G, Orrell C, Mallolas J, Podzamczer D, Trottier B, Zhang W, Sabo JP, Vinisko R, Drulak M, and Quinson AM
- Subjects
- CD4 Lymphocyte Count, Delayed-Action Preparations administration & dosage, Delayed-Action Preparations pharmacokinetics, Double-Blind Method, Female, HIV-1 isolation & purification, Humans, Male, Plasma chemistry, Viral Load, Anti-HIV Agents administration & dosage, Anti-HIV Agents pharmacokinetics, HIV Infections drug therapy, Nevirapine administration & dosage, Nevirapine pharmacokinetics
- Abstract
Background: VERxVE data showed non-inferior virologic efficacy with extended release nevirapine (NVP-XR) dosed 400 mg once daily (QD) versus immediate release nevirapine (NVP-IR) 200 mg twice daily in a double-blind, non-inferiority study in treatment-naïve HIV-1-positive patients., Objective: To study the pharmacokinetics (PK) of the NVP formulations and identify possible associations with demographic factors., Methods: Patients with viral load ≥1000 copies/mL and CD4+ count > 50- <400 cells/mm
3 (males) and >50- <250 cells/mm3 (females) at screening received NVP-IR 200 mg QD during a 14-day lead-in and were then stratified by baseline viral load and randomized to NVP-XR or -IR. NVP trough concentrations at steady state (SS) (Cpre,ss,N ) were measured up to week 48 for all participating patients. In a PK sub-study, SS parameters - AUC0-24 , Cmax , Cmin , and peak-to-trough fluctuation were obtained and analyzed with relative bioavailability assessed at week 4 by plasma collection over 24 h., Results: Trough concentrations were stable from week 4 to week 48 for all patients (n = 1011) with both formulations, with NVP-XR/IR ratios of 0.77-0.82. Overall, 49 patients completed the PK sub-study: 24 XR and 25 IR. NVP-XR showed less peak-to-trough fluctuation (34.5%) than IR (55.2%), and lower AUC0-24 , Cmin , Cmax , and trough concentrations than IR. However, no effect of SS trough concentrations was found on the virologic response proportion at least up to 1000 ng/mL. No significant association was found between NVP PK and gender, race, and viral load., Conclusion: These data suggest NVP-XR achieves lower but effective NVP exposure compared with NVP-IR.- Published
- 2017
- Full Text
- View/download PDF
4. Contribution of Major Metabolites toward Complex Drug-Drug Interactions of Deleobuvir: In Vitro Predictions and In Vivo Outcomes.
- Author
-
Sane RS, Ramsden D, Sabo JP, Cooper C, Rowland L, Ting N, Whitcher-Johnstone A, and Tweedie DJ
- Subjects
- Area Under Curve, Cytochrome P-450 CYP3A Inhibitors metabolism, Cytochrome P-450 Enzyme System metabolism, Female, Hepatocytes metabolism, Humans, Male, Acrylates metabolism, Benzimidazoles metabolism, Drug Interactions physiology
- Abstract
The drug-drug interaction (DDI) potential of deleobuvir, an hepatitis C virus (HCV) polymerase inhibitor, and its two major metabolites, CD 6168 (formed via reduction by gut bacteria) and deleobuvir-acyl glucuronide (AG), was assessed in vitro. Area-under-the-curve (AUC) ratios (AUCi/AUC) were predicted using a static model and compared with actual AUC ratios for probe substrates in a P450 cocktail of caffeine (CYP1A2), tolbutamide (CYP2C9), and midazolam (CYP3A4), administered before and after 8 days of deleobuvir administration to HCV-infected patients. In vitro studies assessed inhibition, inactivation and induction of P450s. Induction was assessed in a short-incubation (10 hours) hepatocyte assay, validated using positive controls, to circumvent cytotoxicity seen with deleobuvir and its metabolites. Overall, P450 isoforms were differentially affected by deleobuvir and its two metabolites. Of note was more potent CYP2C8 inactivation by deleobuvir-AG than deleobuvir and P450 induction by CD 6168 but not by deleobuvir. The predicted net AUC ratios for probe substrates were 2.92 (CYP1A2), 0.45 (CYP2C9), and 0.97 (CYP3A4) compared with clinically observed ratios of 1.64 (CYP1A2), 0.86 (CYP2C9), and 1.23 (CYP3A4). Predictions of DDI using deleobuvir alone would have significantly over-predicted the DDI potential for CYP3A4 inhibition (AUC ratio of 6.15). Including metabolite data brought the predicted net effect close to the observed DDI. However, the static model over-predicted the induction of CYP2C9 and inhibition/inactivation of CYP1A2. This multiple-perpetrator DDI scenario highlights the application of the static model for predicting complex DDI for CYP3A4 and exemplifies the importance of including key metabolites in an overall DDI assessment., (Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics.)
- Published
- 2016
- Full Text
- View/download PDF
5. Nevirapine extended-release formulation tablets in HIV-1-infected children--long-term follow-up.
- Author
-
Anabwani G, Königs C, Giaquinto C, Aslanyan S, Sabo JP, Morrow JS, and Feiterna-Sperling C
- Subjects
- Adolescent, Anti-HIV Agents administration & dosage, Anti-HIV Agents adverse effects, Child, Child, Preschool, Delayed-Action Preparations, Drug-Related Side Effects and Adverse Reactions epidemiology, Follow-Up Studies, HIV Infections epidemiology, Humans, Medication Adherence statistics & numerical data, Nevirapine administration & dosage, Nevirapine adverse effects, Anti-HIV Agents therapeutic use, HIV Infections drug therapy, Nevirapine therapeutic use
- Abstract
In the optional extension of clinical trial 1100.1518 39/40, human immunodeficiency virus-infected patients (aged 3 to <18 years) received ≥48 weeks of treatment with extended-release nevirapine. By last visit, all patients had undetectable viral loads and no new safety signals, demonstrating the safety and efficacy of a once-daily antiretroviral regimen., (© The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2015
- Full Text
- View/download PDF
6. Interactions of the hepatitis C virus protease inhibitor faldaprevir with cytochrome P450 enzymes: in vitro and in vivo correlation.
- Author
-
Sabo JP, Kort J, Ballow C, Kashuba AD, Haschke M, Battegay M, Girlich B, Ting N, Lang B, Zhang W, Cooper C, O'Brien D, Seibert E, Chan TS, Tweedie D, and Li Y
- Subjects
- Adolescent, Adult, Aminoisobutyric Acids, Dose-Response Relationship, Drug, Female, Healthy Volunteers, Hepatitis C metabolism, Humans, In Vitro Techniques, Isoenzymes metabolism, Leucine analogs & derivatives, Male, Microsomes, Liver drug effects, Midazolam pharmacokinetics, Middle Aged, Proline analogs & derivatives, Quinolines, Warfarin pharmacokinetics, Young Adult, Cytochrome P-450 Enzyme Inhibitors pharmacology, Cytochrome P-450 Enzyme System metabolism, Oligopeptides pharmacology, Protease Inhibitors pharmacology, Thiazoles pharmacology
- Abstract
The potential inhibition of the major human cytochrome P450 (CYP) enzymes by faldaprevir was evaluated both in vitro and in clinical studies (healthy volunteers and hepatitis C virus [HCV] genotype 1-infected patients). In vitro studies indicated that faldaprevir inhibited CYP2B6, CYP2C9, and CYP3A, and was a weak-to-moderate inactivator of CYP3A4. Faldaprevir 240 mg twice daily in healthy volunteers demonstrated moderate inhibition of hepatic and intestinal CYP3A (oral midazolam: 2.96-fold increase in AUC(0-24 h)), weak inhibition of hepatic CYP3A (intravenous midazolam: 1.56-fold increase in AUC(0-24 h)), weak inhibition of CYP2C9 ([S]-warfarin: 1.29-fold increase in AUC(0-120 h)), and had no relevant effects on CYP1A2, CYP2B6, or CYP2D6. Faldaprevir 120 mg once daily in HCV-infected patients demonstrated weak inhibition of hepatic and intestinal CYP3A (oral midazolam: 1.52-fold increase in AUC(0-∞)), and had no relevant effects on CYP2C9 or CYP1A2. In vitro drug-drug interaction predictions based on inhibitor concentration ([I])/inhibition constant (Ki) ratios tended to overestimate clinical effects and a net-effect model provided a more accurate approach. These studies suggest that faldaprevir shows a dose-dependent inhibition of CYP3A and CYP2C9, and does not induce CYP isoforms., (© 2015, The American College of Clinical Pharmacology.)
- Published
- 2015
- Full Text
- View/download PDF
7. Efficacy and safety of faldaprevir, deleobuvir, and ribavirin in treatment-naive patients with chronic hepatitis C virus infection and advanced liver fibrosis or cirrhosis.
- Author
-
Zeuzem S, Soriano V, Asselah T, Gane EJ, Bronowicki JP, Angus P, Lohse AW, Stickel F, Müllhaupt B, Roberts S, Schuchmann M, Manns M, Bourlière M, Buti M, Stern JO, Gallivan JP, Voss F, Sabo JP, Böcher W, and Mensa FJ
- Subjects
- Acrylates adverse effects, Adult, Aged, Aged, 80 and over, Aminoisobutyric Acids, Antiviral Agents adverse effects, Antiviral Agents therapeutic use, Benzimidazoles adverse effects, Female, Humans, Leucine analogs & derivatives, Male, Middle Aged, Oligopeptides adverse effects, Proline analogs & derivatives, Quinolines, Ribavirin adverse effects, Thiazoles adverse effects, Young Adult, Acrylates therapeutic use, Benzimidazoles therapeutic use, Hepatitis C, Chronic complications, Hepatitis C, Chronic drug therapy, Liver Cirrhosis complications, Liver Cirrhosis drug therapy, Oligopeptides therapeutic use, Ribavirin therapeutic use, Thiazoles therapeutic use
- Abstract
Patients with advanced hepatic fibrosis or cirrhosis with chronic hepatitis C virus (HCV) infection represent an unmet need. The HCV NS3/4A inhibitor, faldaprevir, was evaluated in combination with the nonnucleoside NS5B inhibitor, deleobuvir, with or without ribavirin in treatment-naive patients with HCV genotype 1 infection in the SOUND-C2 study. Here, the efficacy and safety of this interferon-free regimen in a subset of patients with advanced liver fibrosis, including those with compensated cirrhosis, were assessed. Patients (n=362) were randomized to once-daily faldaprevir with either twice-daily (BID) or three-times-daily (TID) deleobuvir for 16 (TID16W), 28 (TID28W and BID28W), or 40 (TID40W) weeks with or without ribavirin (TID28W-NR). Patients were classified according to fibrosis stage (F0 to F2 versus F3 to F4) and the presence of cirrhosis (yes/no). In total, 85 (24%) patients had advanced fibrosis/cirrhosis (F3 to F4) and 33 (9%) had cirrhosis. Within each treatment arm, differences in rates of sustained virologic response 12 weeks after completion of treatment (SVR12) between patients with mild to moderate fibrosis (F0 to F2) versus F3 to F4 did not show a consistent pattern and were not statistically significant (63% versus 47% for TID16W, 53% versus 76% for TID28W, 48% versus 67% for TID40W, 70% versus 67% for BID28W, and 40% versus 36% for TID28W-NR, respectively; P > 0.05 for each arm). The most frequent adverse events in patients with/without cirrhosis were gastrointestinal and skin events, which were mostly mild or moderate in intensity. The degree of liver fibrosis did not appear to affect the probability of achieving SVR12 following treatment with the interferon-free regimen of faldaprevir, deleobuvir, and ribavirin. (This study has been registered at ClinicalTrials.gov under registration no. NCT01132313.)., (Copyright © 2015, American Society for Microbiology. All Rights Reserved.)
- Published
- 2015
- Full Text
- View/download PDF
8. Mass balance, metabolite profile, and in vitro-in vivo comparison of clearance pathways of deleobuvir, a hepatitis C virus polymerase inhibitor.
- Author
-
Chen LZ, Sabo JP, Philip E, Rowland L, Mao Y, Latli B, Ramsden D, Mandarino DA, and Sane RS
- Subjects
- Adolescent, Adult, Carbon Radioisotopes, Feces chemistry, Gastrointestinal Tract, Half-Life, Healthy Volunteers, Hepatobiliary Elimination, Hepatocytes metabolism, Humans, Liver, Male, Middle Aged, Protein Binding, Young Adult, Acrylates adverse effects, Acrylates blood, Acrylates pharmacokinetics, Acrylates urine, Benzimidazoles adverse effects, Benzimidazoles blood, Benzimidazoles pharmacokinetics, Benzimidazoles urine, Hepacivirus enzymology, Hepatitis C drug therapy
- Abstract
The pharmacokinetics, mass balance, and metabolism of deleobuvir, a hepatitis C virus (HCV) polymerase inhibitor, were assessed in healthy subjects following a single oral dose of 800 mg of [(14)C]deleobuvir (100 μCi). The overall recovery of radioactivity was 95.2%, with 95.1% recovered from feces. Deleobuvir had moderate to high clearance, and the half-life of deleobuvir and radioactivity in plasma were ∼ 3 h, indicating that there were no metabolites with half-lives significantly longer than that of the parent. The most frequently reported adverse events (in 6 of 12 subjects) were gastrointestinal disorders. Two major metabolites of deleobuvir were identified in plasma: an acyl glucuronide and an alkene reduction metabolite formed in the gastrointestinal (GI) tract by gut bacteria (CD 6168), representing ∼ 20% and 15% of the total drug-related material, respectively. Deleobuvir and CD 6168 were the main components in the fecal samples, each representing ∼ 30 to 35% of the dose. The majority of the remaining radioactivity found in the fecal samples (∼ 21% of the dose) was accounted for by three metabolites in which deleobuvir underwent both alkene reduction and monohydroxylation. In fresh human hepatocytes that form biliary canaliculi in sandwich cultures, the biliary excretion for these excretory metabolites was markedly higher than that for deleobuvir and CD 6168, implying that rapid biliary elimination upon hepatic formation may underlie the absence of these metabolites in circulation. The low in vitro clearance was not predictive of the observed in vivo clearance, likely because major deleobuvir biotransformation occurred by non-CYP450-mediated enzymes that are not well represented in hepatocyte-based in vitro models., (Copyright © 2015, American Society for Microbiology. All Rights Reserved.)
- Published
- 2015
- Full Text
- View/download PDF
9. Effect of the hepatitis C virus protease inhibitor faldaprevir on the pharmacokinetics of an oral contraceptive containing ethinylestradiol and levonorgestrel in healthy female volunteers.
- Author
-
Sabo JP, Lang B, Elgadi M, and Huang F
- Subjects
- Administration, Oral, Adolescent, Adult, Aminoisobutyric Acids, Area Under Curve, Bilirubin blood, Contraceptives, Oral, Combined administration & dosage, Drug Combinations, Drug Interactions, Ethinyl Estradiol administration & dosage, Ethinyl Estradiol adverse effects, Ethinyl Estradiol blood, Female, Half-Life, Humans, Leucine analogs & derivatives, Levonorgestrel administration & dosage, Levonorgestrel adverse effects, Levonorgestrel blood, Oligopeptides administration & dosage, Oligopeptides adverse effects, Proline analogs & derivatives, Protease Inhibitors administration & dosage, Protease Inhibitors pharmacokinetics, Quinolines, Thiazoles administration & dosage, Thiazoles adverse effects, Viral Nonstructural Proteins antagonists & inhibitors, Young Adult, Contraceptives, Oral, Combined pharmacokinetics, Ethinyl Estradiol pharmacokinetics, Levonorgestrel pharmacokinetics, Oligopeptides pharmacokinetics, Thiazoles pharmacokinetics
- Abstract
Faldaprevir is a potent hepatitis C virus (HCV) NS3/4A protease inhibitor. Faldaprevir is known to inhibit P-glycoprotein, CYP3A4, and UDP-glucuronosyltransferase 1A1. This study evaluated the effect of steady-state 240 mg faldaprevir on the pharmacokinetics (PK) of an oral contraceptive containing ethinylestradiol (EE) and levonorgestrel (LNG) in healthy premenopausal women. In period 1, subjects received EE/LNG once daily (QD) for 14 days. Blood samples were taken on days 1, 11, and 12, with intensive PK blood sampling for EE and LNG on day 13. In period 2, subjects received EE-LNG QD and 240 mg faldaprevir QD on days 14 to 21 (240 mg faldaprevir twice daily on day 14). Blood samples were taken on days 14, 19, and 20, with PK profiling samples obtained for EE and LNG on day 21. A total of 15/16 subjects completed the study. Overall, EE and LNG exposure (assessed by the area under the curve) was approximately 1.4-fold higher when EE and LNG were coadministered with faldaprevir than when administered alone. Median t1/2 (terminal half-life in plasma at steady state) values were prolonged for both EE (2.4 h longer) and LNG (4.7 h longer) when EE and LNG were coadministered with faldaprevir. The mean oral clearance and apparent volume of distribution of both EE and LNG were lower (∼ 30%) when EE and LNG were coadministered with faldaprevir. Coadministration of faldaprevir and an oral contraceptive resulted in a moderate increase in exposure to both EE and LNG. However, this increase was not considered clinically meaningful, and no dose adjustment of oral contraceptives was deemed necessary. (This study has been registered at ClinicalTrials.gov under registration number NCT01570244.)., (Copyright © 2015, American Society for Microbiology. All Rights Reserved.)
- Published
- 2015
- Full Text
- View/download PDF
10. Clinical assessment of potential drug interactions of faldaprevir, a hepatitis C virus protease inhibitor, with darunavir/ritonavir, efavirenz, and tenofovir.
- Author
-
Sabo JP, Kort J, Ballow C, Haschke M, Battegay M, Fuhr R, Girlich B, Schobelock M, Feifel U, Lang B, Li Y, and Elgadi M
- Subjects
- Adenine pharmacology, Adenine therapeutic use, Adult, Alkynes, Aminoisobutyric Acids, Anti-HIV Agents therapeutic use, Antiretroviral Therapy, Highly Active, Benzoxazines therapeutic use, Coinfection, Cyclopropanes, Darunavir, Drug Interactions, Female, HIV Infections drug therapy, HIV-1 drug effects, HIV-1 genetics, Healthy Volunteers, Hepacivirus drug effects, Hepacivirus genetics, Hepatitis C drug therapy, Hepatitis C virology, Humans, Leucine analogs & derivatives, Male, Middle Aged, Oligopeptides therapeutic use, Organophosphonates therapeutic use, Proline analogs & derivatives, Protease Inhibitors therapeutic use, Quinolines, Ritonavir therapeutic use, Sulfonamides therapeutic use, Tenofovir, Thiazoles therapeutic use, Young Adult, Adenine analogs & derivatives, Anti-HIV Agents pharmacology, Benzoxazines pharmacology, Oligopeptides pharmacology, Organophosphonates pharmacology, Protease Inhibitors pharmacology, Ritonavir pharmacology, Sulfonamides pharmacology, Thiazoles pharmacology
- Abstract
Background: Faldaprevir is a potent, once-daily hepatitis C virus (HCV) NS3/4A protease inhibitor. Studies were performed to investigate potential drug interactions between faldaprevir and the commonly used antiretrovirals darunavir/ritonavir, efavirenz, and tenofovir to guide the coadministration of faldaprevir with these agents in human immunodeficiency virus/HCV-coinfected patients., Methods: In 3 open-label, phase 1 pharmacokinetic (PK) studies, healthy adult volunteers received (1) darunavir/ritonavir (800 mg/100 mg once daily) with and without faldaprevir (240 mg once daily); (2) faldaprevir (240 mg twice daily) with and without efavirenz (600 mg once daily); or (3) faldaprevir (240 mg twice daily) or tenofovir (300 mg once daily) alone and in combination. To assess potential drug interactions, geometric mean ratios and 90% confidence intervals for PK parameters were calculated. Safety was evaluated., Results: Efavirenz decreased faldaprevir area under the concentration-time curve (AUC) by 35%, Cmax by 28%, and Cmin by 46%, consistent with induction of CYP3A by efavirenz. Tenofovir decreased faldaprevir AUC by 22%, which was not considered to be clinically relevant. Faldaprevir had no clinically relevant effects on darunavir or tenofovir PK (15% and 22% AUC increase, respectively). Adverse events were consistent with the known safety profiles of faldaprevir and the antiretrovirals being examined., Conclusions: No clinically significant interactions were observed between faldaprevir and darunavir/ritonavir or tenofovir. A potentially clinically relevant decrease in faldaprevir exposure was observed when coadministered with efavirenz; this decrease can be managed using the higher of the 2 faldaprevir doses tested in phase 3 trials (240 mg once daily as opposed to 120 mg once daily)., (© The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2014
- Full Text
- View/download PDF
11. Steady-state pharmacokinetics of nevirapine extended-release tablets in HIV-1-infected children and adolescents: an open-label, multiple-dose, cross-over study.
- Author
-
Giaquinto C, Anabwani G, Feiterna-Sperling C, Nuttall J, Mompati K, Königs C, Mensa FJ, Sabo JP, Yong CL, MacGregor TR, Nguyen T, and Quinson AM
- Subjects
- Adolescent, Anti-HIV Agents administration & dosage, Anti-HIV Agents adverse effects, Anti-HIV Agents pharmacology, CD4 Lymphocyte Count, Child, Child, Preschool, Cross-Over Studies, Delayed-Action Preparations administration & dosage, Delayed-Action Preparations adverse effects, Delayed-Action Preparations pharmacology, Drug-Related Side Effects and Adverse Reactions epidemiology, Drug-Related Side Effects and Adverse Reactions pathology, Female, HIV Infections drug therapy, Humans, Male, Nevirapine administration & dosage, Nevirapine adverse effects, Nevirapine pharmacology, Tablets administration & dosage, Tablets adverse effects, Tablets pharmacokinetics, Tablets pharmacology, Viral Load, Anti-HIV Agents pharmacokinetics, Delayed-Action Preparations pharmacokinetics, Nevirapine pharmacokinetics
- Abstract
Background: To compare steady-state (ss) pharmacokinetic targets of nevirapine extended-release (NVP-XR) tablets once-daily (QD) with immediate-release (NVP-IR) tablet or oral suspension twice-daily in HIV-1-infected children and adolescents., Methods: Phase I, open-label, multidose, cross-over study with optional extension phase, in 85 patients 3 to <18 years of age, previously on an NVP-IR-based regimen for ≥18 weeks with baseline viral load <50 copies/mL. Patients were stratified by age, treated with NVP-IR twice-daily for 11 days, then NVP-XR QD for 10 days. Cpre,ss (steady-state, predose concentrations) was obtained from all, and 12-hour NVP-IR and 24-hour NVP-XR steady-state pharmacokinetic profiles were obtained in the pharmacokinetic substudy. Viral loads, CD4 counts and adverse events (AEs) were monitored., Results: Eighty patients completed the trial. Adjusted geometric mean (gMean) Cpre,ss for NVP-XR and NVP-IR exceeded the target of 3000 ng/mL, and the adjusted gMean NVP-XR:NVP-IR ratio (90% confidence interval) for QD normalized and un-normalized Cpre,ss were 91.2% (83.5-99.6%) and 91.8% (83.7-100.7%). gMean 24-hour area under the curve at steady-state NVP-XR:NVP-IR for un-normalized dose was 90.4% and un-normalized Cpre,ss NVP-XR:NVP-IR were 91.0%, 81.9% and 103.7% for the 3 age groups, 3 to <6, 6 to <12 and 12 to <18 years, respectively. gMean values indicated no exposure to subtherapeutic NVP concentrations and viral suppression was adequate and maintained in all QD groups. Most AEs were mild and similar between age groups. No serious or Division of AIDS Grade 4 AEs or AE related treatment discontinuations occurred., Conclusions: NVP-XR exhibited adequate trough concentrations with equivalent area under the curve at steady-state relative to NVP-IR. NVP-XR was well-tolerated and is a valuable treatment option for HIV-infected children and adolescents.
- Published
- 2014
- Full Text
- View/download PDF
12. Effect of tipranavir/ritonavir combination on the pharmacokinetics of tadalafil in healthy volunteers.
- Author
-
Garraffo R, Lavrut T, Ferrando S, Durant J, Rouyrre N, MacGregor TR, Sabo JP, and Dellamonica P
- Subjects
- Adult, Biological Availability, Carbolines adverse effects, Carbolines blood, Cross-Over Studies, Drug Interactions, HIV Protease Inhibitors adverse effects, HIV Protease Inhibitors blood, Half-Life, Humans, Male, Metabolic Clearance Rate, Phosphodiesterase 5 Inhibitors adverse effects, Phosphodiesterase 5 Inhibitors blood, Pyridines adverse effects, Pyridines blood, Pyrones adverse effects, Pyrones blood, Ritonavir adverse effects, Sulfonamides, Tadalafil, Young Adult, Carbolines pharmacokinetics, HIV Protease Inhibitors pharmacokinetics, Phosphodiesterase 5 Inhibitors pharmacokinetics, Pyridines pharmacokinetics, Pyrones pharmacokinetics, Ritonavir pharmacology
- Abstract
This study evaluated the effects of single-dose administration and steady-state concentrations of tipranavir 500 mg and ritonavir 200 mg (TPV/r) combination on the pharmacokinetics of tadalafil 10 mg (TAD) in an open-label study. Seventeen healthy male volunteers received sequential dosing of the studied product: TAD (day 1) alone in a single dose for 7 days followed by TAD (day 8) in a single dose with TPV/r (500/200 mg twice daily, days 8-18). Pharmacokinetic parameters were determined in a noncompartmental analysis. The geometric mean ratio and 90% confidence interval were used to evaluate drug interactions. The effect of a single dose of TAD on the pharmacokinetics of TPV/r resulted in a small decrease in exposure after either first-dose or steady-state TPV/r (geometric mean ratios [90% confidence interval]: area under the concentration-time curve, 0.85 [0.74-0.97]). In contrast, coadministration of TAD exposure was increased significantly (2.33 [2.02-2.69]) when administered with the first dose of TPV/r but not when TPV/r steady state was reached (1.01 [0.83-1.21]). Antiretroviral activity may not be reduced, but the dose of TAD should be reduced at the start of TPV/r therapy and then a full dose can be resumed after steady state is reached.
- Published
- 2011
- Full Text
- View/download PDF
13. Effects of tipranavir, darunavir, and ritonavir on platelet function, coagulation, and fibrinolysis in healthy volunteers.
- Author
-
Kort JJ, Aslanyan S, Scherer J, Sabo JP, Kohlbrenner V, and Robinson P
- Subjects
- Adult, Blood Coagulation drug effects, Blood Coagulation Factors drug effects, Darunavir, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Prospective Studies, Fibrinolysis drug effects, HIV Protease Inhibitors pharmacology, Platelet Aggregation drug effects, Pyridines pharmacology, Pyrones pharmacology, Ritonavir pharmacology, Sulfonamides pharmacology
- Abstract
The use of HIV protease inhibitors (PIs) as part of antiretroviral therapy in the treatment of HIV-1 infection may be associated with an increased risk of bleeding. This prospective, randomized, open-label trial in healthy volunteers compared the effects of tipranavir/ritonavir (TPV/r), darunavir/ ritonavir (DRV/r), and ritonavir (RTV) alone on platelet aggregation after a single dose and at steady-state concentrations. Subjects were selected on the basis of normal platelet aggregation and arachidonic acid (AA)-induced platelet aggregation inhibition after administration of a single 325-mg dose of aspirin. All 3 PI therapies were administered twice daily for 10 days. In some but not all subjects, TPV/r inhibited AA-induced platelet aggregation and prolonged PFA-100® closure time with collagen-epinephrine cartridge, which was of lesser magnitude and consistency compared with aspirin, but greater when compared to DRV/r and RTV. At least 2 subjects in each treatment arm showed complete inhibition of AA-induced platelet aggregation on treatment, and the magnitude of change in all platelet-function tests did not correlate with PI plasma concentrations. Effects of TPV/r on platelet aggregation were reversed 24 hours after the last TPV/r dose. None of the PI treatments tested were associated with increases in bleeding time, decreases in plasma coagulation factors, or increase in fibrinolysis. There was large inter-patient variability in antiplatelet effect for all PI treatments, ranging from no effect to complete inhibition of AA-induced platelet aggregation.
- Published
- 2011
- Full Text
- View/download PDF
14. Lack of a pharmacokinetic interaction between steady-state tipranavir/ritonavir and single-dose valacyclovir in healthy volunteers.
- Author
-
Sabo JP, Cong XJ, Kraft MF, Wallace L, Castles MA, Mauss S, and MacGregor TR
- Subjects
- Acyclovir administration & dosage, Acyclovir adverse effects, Acyclovir pharmacokinetics, Adult, Anti-HIV Agents administration & dosage, Anti-HIV Agents adverse effects, Anti-HIV Agents pharmacology, Antiviral Agents administration & dosage, Antiviral Agents adverse effects, Antiviral Agents pharmacokinetics, Area Under Curve, Chromatography, Liquid, Cross-Over Studies, Drug Interactions, Drug Therapy, Combination, Female, HIV Protease Inhibitors administration & dosage, HIV Protease Inhibitors adverse effects, HIV Protease Inhibitors pharmacology, Humans, Male, Middle Aged, Prodrugs, Pyridines administration & dosage, Pyridines adverse effects, Pyrones administration & dosage, Pyrones adverse effects, Ritonavir administration & dosage, Ritonavir adverse effects, Sulfonamides, Tandem Mass Spectrometry, Valacyclovir, Valine administration & dosage, Valine adverse effects, Valine pharmacokinetics, Acyclovir analogs & derivatives, Pyridines pharmacology, Pyrones pharmacology, Ritonavir pharmacology, Valine analogs & derivatives
- Abstract
Objective: This study assessed the single-dose pharmacokinetics of the herpes antiviral acyclovir (administered as the pro-drug valacyclovir) alone and in combination with twice-daily 200 mg ritonavir-boosted tipranavir (500 mg) at steady state., Methods: The study was an open label, one-sequence cross-over pharmacokinetic study in HIV-negative adults. Plasma drug concentrations were measured by validated LC/MS/MS assays; pharmacokinetics (AUC, C(max)) were determined using noncompartmental methods. The geometric mean ratio and 90% confidence interval [GMR, 90% CI] were used to evaluate the drug interaction., Results: Twenty-six of 29 subjects completed the trial. With steady-state tipranavir/ritonavir, acyclovir C(max) decreased 4.9% [0.95, 0.88-1.02] and AUC increased 6.6% [1.07, 1.04-1.09]. The majority of subjects experienced at least one adverse event, most of which were mild gastrointestinal disorders. Three subjects discontinued tipranavir/ritonavir treatment as a result of drug-related increases in ALT/AST, including one subject who experienced mild upper abdominal pain. All subjects recovered without sequelae., Conclusions: When administered as a single dose of valacyclovir with steady-state tipranavir/ritonavir, there were no clinically important changes in acyclovir pharmacokinetics. This result indicates that valacyclovir can be co-administered safely with no dose adjustments.
- Published
- 2011
- Full Text
- View/download PDF
15. A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir.
- Author
-
Dumond JB, Vourvahis M, Rezk NL, Patterson KB, Tien HC, White N, Jennings SH, Choi SO, Li J, Wagner MJ, La-Beck NM, Drulak M, Sabo JP, Castles MA, Macgregor TR, and Kashuba AD
- Subjects
- ATP Binding Cassette Transporter, Subfamily B, Member 1 metabolism, Adult, Area Under Curve, Cytochrome P-450 Enzyme System metabolism, Drug Combinations, Drug Interactions, Enzyme Induction drug effects, Enzyme Inhibitors pharmacology, Female, Genotype, HIV Protease Inhibitors pharmacology, Humans, Intestinal Mucosa metabolism, Liver metabolism, Male, Pharmaceutical Preparations administration & dosage, Pharmaceutical Preparations metabolism, Phenotype, Polymorphism, Single Nucleotide, Sulfonamides, Young Adult, ATP Binding Cassette Transporter, Subfamily B, Member 1 drug effects, Anti-HIV Agents pharmacology, Cytochrome P-450 Enzyme System drug effects, Pyridines pharmacology, Pyrones pharmacology, Ritonavir pharmacology
- Abstract
The effects of tipranavir/ritonavir (TPV/r) on hepatic and intestinal P-glycoprotein (P-gp) and cytochrome P450 (CYP) enzyme activity were evaluated in 23 volunteers. The subjects received oral (p.o.) caffeine, warfarin + vitamin K, omeprazole, dextromethorphan, and midazolam and digoxin (p.o. and intravenous (i.v.)) at baseline, during the first three doses of TPV/r (500 mg/200 mg b.i.d.), and at steady state. Plasma area under the curve (AUC)(0-infinity) and urinary metabolite ratios were used for quantification of protein activities. A single dose of TPV/r had no effect on the activity of CYP1A2 and CYP2C9; it weakly inhibited CYP2C19 and P-gp; and it potently inhibited CYP2D6 and CYP3A. Multiple dosing produced weak induction of CYP1A2, moderate induction of CYP2C19, potent induction of intestinal P-gp, and potent inhibition of CYP2D6 and CYP3A, with no significant effects on CYP2C9 and hepatic P-gp. Several P450/transporter single-nucleotide polymorphisms correlated with the baseline phenotype but not with the extent of inhibition or induction. Although mixed induction and inhibition are present, this approach offers an understanding of drug interaction mechanisms and ultimately assists in optimizing the clinical use of TPV/r.
- Published
- 2010
- Full Text
- View/download PDF
16. Pharmacokinetic characterization of three doses of tipranavir boosted with ritonavir on highly active antiretroviral therapy in treatment-experienced HIV-1 patients.
- Author
-
Goebel FD, MacGregor TR, Sabo JP, Castles M, Johnson PA, Legg D, and McCallister S
- Subjects
- Adult, Anti-HIV Agents administration & dosage, Antiretroviral Therapy, Highly Active methods, Area Under Curve, CD4 Lymphocyte Count, Female, HIV Infections immunology, HIV Infections virology, Humans, Male, Pyridines administration & dosage, Pyrones administration & dosage, Ritonavir administration & dosage, Sulfonamides, Viral Load drug effects, Anti-HIV Agents pharmacokinetics, HIV Infections drug therapy, HIV-1, Pyridines pharmacokinetics, Pyrones pharmacokinetics, Ritonavir pharmacokinetics
- Abstract
Purpose: This study characterized the pharmacokinetic effects, safety, and antiretroviral activity of three different doses of the nonpeptidic protease inhibitor tipranavir, in combination with ritonavir administered twice daily for 28 days, on a number of triple-combination regimens containing a nonnucleoside reverse transcriptase inhibitor (efavirenz or nevirapine) plus two nucleoside reverse transcriptase inhibitors (abacavir, didanosine, lamivudine, stavudine, and zidovudine) or a three nucleoside reverse transcriptase inhibitor combination (zidovudine, lamivudine, and abacavir)., Methods: The study enrolled 208 HIV-1-positive patients who had been on stable antiretroviral treatment for at least 12 weeks prior to study entry and had an HIV-1 RNA load of delta 20,000 copies/mL. The patients were randomized to receive one of three dose combinations of tipranavir and ritonavir (1250/100 mg, 750/100 mg, and 250/200 mg) in addition to their antiretroviral (ARV) regimen for the next 22 days. The effects of twice-daily tipranavir and ritonavir combinations on the steady-state pharmacokinetics of the antiretrovirals were assessed by comparing pharmacokinetic parameters at baseline and after 3 weeks of coadministration., Results: No clinically relevant changes were observed in the Cmin, Cmax, or AUC parameters for nevirapine, efavirenz, lamivudine, stavudine, or didanosine, when coadministered with tipranavir and ritonavir at the dose combinations studied. All three dose combinations of tipranavir and ritonavir decreased the systemic exposure of abacavir (by 35% to 44%) and zidovudine (by 31% to 42%). Consistent with previous tipranavir studies, gastrointestinal adverse events were those most frequently observed. These reactions tended to be mild, with the majority being of Grade 1, and only 8 being of Grade 3 or 4 in intensity. Virologic response improved from 40.4% of participants at baseline with <50 copies/mL to 67.6% at Day 28 of study following addition of tipranavir and ritonavir., Conclusions: Tipranavir coadministered with ritonavir has been demonstrated to be safe, effective, and pose little potential for clinically meaningful drug interactions when added to the highly active antiretroviral therapy regimens containing nevirapine, efavirenz, lamivudine, stavudine, or didanosine.
- Published
- 2010
- Full Text
- View/download PDF
17. Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone.
- Author
-
Bruce RD, Altice FL, Moody DE, Lin SN, Fang WB, Sabo JP, Wruck JM, Piliero PJ, Conner C, Andrews L, and Friedland GH
- Subjects
- Adult, Anti-Retroviral Agents pharmacokinetics, Anti-Retroviral Agents therapeutic use, Buprenorphine therapeutic use, Drug Interactions, Drug Therapy, Combination adverse effects, Female, HIV Infections complications, HIV Infections drug therapy, Humans, Male, Middle Aged, Naloxone therapeutic use, Narcotic Antagonists pharmacokinetics, Narcotic Antagonists therapeutic use, Opioid-Related Disorders complications, Opioid-Related Disorders drug therapy, Pyridines therapeutic use, Pyrones therapeutic use, Ritonavir therapeutic use, Sulfonamides, Treatment Outcome, Buprenorphine pharmacokinetics, HIV Seronegativity, Naloxone pharmacokinetics, Pyridines pharmacokinetics, Pyrones pharmacokinetics, Ritonavir pharmacokinetics
- Abstract
HIV-infected patients with opioid dependence often require opioid replacement therapy. Pharmacokinetic interactions between HIV therapy and opioid dependence treatment medications can occur. HIV-seronegative subjects stabilized on at least 3 weeks of buprenorphine/naloxone (BUP/NLX) therapy sequentially underwent baseline and steady-state pharmacokinetic evaluation of open-label, twice daily tipranavir 500 mg co-administered with ritonavir 200 mg (TPV/r). Twelve subjects were enrolled and 10 completed the study. Prior to starting TPV/r, the geometric mean BUP AUC(0-24h) and C(max) were 43.9 ng h/mL and 5.61 ng/mL, respectively. After achieving steady-state with TPV/r (> or = 7 days), these values were similar at 43.7 ng h/mL and 4.84 ng/mL, respectively. Similar analyses for norBUP, the primary metabolite of BUP, demonstrated a reduction in geometric mean for AUC(0-24h) [68.7-14.7 ng h/mL; ratio=0.21 (90% CI 0.19-0.25)] and C(max) [4.75-0.94 ng/mL; ratio=0.20 (90% CI 0.17-0.23)]. The last measurable NLX concentration (C(last)) in the concentration-time profile, never measured in previous BUP/NLX interaction studies with antiretroviral medications, was decreased by 20%. Despite these pharmacokinetic effects on BUP metabolites and NLX, no clinical opioid withdrawal symptoms were noted. TPV steady-state AUC(0-12h) and C(max) decreased 19% and 25%, respectively, and C(min) was relatively unchanged when compared to historical control subjects receiving TPV/r alone. No dosage modification of BUP/NLX is required when co-administered with TPV/r. Though mechanistically unclear, it is likely that decreased plasma RTV levels while on BUP/NLX contributed substantially to the decrease in TPV levels. BUP/NLX and TPV/r should therefore be used cautiously to avoid decreased efficacy of TPV in patients taking these agents concomitantly.
- Published
- 2009
- Full Text
- View/download PDF
18. Lack of effect of efavirenz on the pharmacokinetics of tipranavir-ritonavir in healthy volunteers.
- Author
-
la Porte CJ, Sabo JP, Béïque L, and Cameron DW
- Subjects
- Adolescent, Adult, Alkynes, Anti-HIV Agents pharmacology, Cyclopropanes, Drug Interactions, Female, Humans, Male, Middle Aged, Sulfonamides, Anti-HIV Agents pharmacokinetics, Benzoxazines pharmacology, Pyridines pharmacokinetics, Pyrones pharmacokinetics, Ritonavir pharmacokinetics
- Abstract
Previously it has been shown that tipranavir-ritonavir (TPV/r) does not affect efavirenz (EFV) plasma concentrations. This study investigates the effect of steady-state EFV on steady-state TPV/r pharmacokinetics. This was a single-center, open-label, multiple-dose study of healthy adult female and male volunteers. TPV/r 500/200 mg twice a day (BID) was given with food for 24 days. After dosing with TPV/r for 10 days, EFV 600 mg once a day was added to the regimen. Intensive pharmacokinetic (PK) sampling was done on days 10 and 24. Validated bioanalytical high-pressure liquid chromatography-tandem mass spectrometry methods were used to determine plasma tipranavir (TPV), ritonavir (RTV), and EFV concentrations. Thirty-four subjects were entered into the study, and 16 subjects completed it. The geometric mean ratios (90% confidence intervals) for TPV and RTV area under the curves, C(max)s, and C(min)s comparing TPV/r alone and in combination with EFV were 0.97 (0.87 to 1.09), 0.92 (0.81 to 1.03), and 1.19 (0.93 to 1.54) for TPV and 1.03 (0.78 to 1.38), 0.92 (0.65 to 1.30), and 1.04 (0.72 to 1.48) for RTV. Frequently observed adverse events were diarrhea, headache, dizziness, abnormal dreams, and rash. EFV had no effect on the steady-state PK of TPV or RTV, with the exception of a 19% increase in the TPV C(min), which is not clinically relevant. TPV/r can be safely coadministered with EFV and without the need for a dose adjustment.
- Published
- 2009
- Full Text
- View/download PDF
19. Differential effects of tipranavir plus ritonavir on atorvastatin or rosuvastatin pharmacokinetics in healthy volunteers.
- Author
-
Pham PA, la Porte CJ, Lee LS, van Heeswijk R, Sabo JP, Elgadi MM, Piliero PJ, Barditch-Crovo P, Fuchs E, Flexner C, and Cameron DW
- Subjects
- Adolescent, Adult, Aged, Anti-HIV Agents adverse effects, Atorvastatin, Drug Interactions, Female, Fluorobenzenes adverse effects, Heptanoic Acids adverse effects, Humans, Male, Middle Aged, Pyridines adverse effects, Pyrimidines adverse effects, Pyrones adverse effects, Pyrroles adverse effects, Ritonavir adverse effects, Rosuvastatin Calcium, Sulfonamides adverse effects, Young Adult, Anti-HIV Agents pharmacokinetics, Fluorobenzenes pharmacokinetics, Heptanoic Acids pharmacokinetics, Pyridines pharmacokinetics, Pyrimidines pharmacokinetics, Pyrones pharmacokinetics, Pyrroles pharmacokinetics, Ritonavir pharmacokinetics, Sulfonamides pharmacokinetics
- Abstract
To identify pharmacokinetic (PK) drug-drug interactions between tipranavir-ritonavir (TPV/r) and rosuvastatin and atorvastatin, we conducted two prospective, open-label, single-arm, two-period studies. The geometric mean (GM) ratio was 1.37 (90% confidence interval [CI], 1.15 to 1.62) for the area under the concentration-time curve (AUC) for rosuvastatin and 2.23 (90% CI, 1.83 to 2.72) for the maximum concentration of drug in serum (Cmax) for rosuvastatin with TPV/r at steady state versus alone. The GM ratio was 9.36 (90% CI, 8.02 to 10.94) for the AUC of atorvastatin and 8.61 (90% CI, 7.25 to 10.21) for the Cmax of atorvastatin with TPV/r at steady state versus alone. Tipranavir PK parameters were not affected by single-dose rosuvastatin or atorvastatin. Mild gastrointestinal intolerance, headache, and mild reversible liver enzyme elevations (grade 1 and 2) were the most commonly reported adverse drug reactions. Based on these interactions, we recommend low initial doses of rosuvastatin (5 mg) and atorvastatin (10 mg), with careful clinical monitoring of rosuvastatin- or atorvastatin-related adverse events when combined with TPV/r.
- Published
- 2009
- Full Text
- View/download PDF
20. Interaction studies of tipranavir-ritonavir with clarithromycin, fluconazole, and rifabutin in healthy volunteers.
- Author
-
la Porte CJ, Sabo JP, Elgadi M, and Cameron DW
- Subjects
- Adolescent, Adult, Anti-HIV Agents administration & dosage, Anti-HIV Agents therapeutic use, Clarithromycin administration & dosage, Drug Interactions, Female, Fluconazole administration & dosage, HIV Protease Inhibitors administration & dosage, HIV Protease Inhibitors therapeutic use, Humans, Male, Middle Aged, Pyridines administration & dosage, Pyrones administration & dosage, Rifabutin administration & dosage, Ritonavir administration & dosage, Sulfonamides, Clarithromycin therapeutic use, Fluconazole therapeutic use, Pyridines therapeutic use, Pyrones therapeutic use, Rifabutin therapeutic use, Ritonavir therapeutic use
- Abstract
Three separate controlled, two-period studies with healthy volunteers assessed the pharmacokinetic interactions between tipranavir-ritonavir (TPV/r) in a 500/200-mg dose and 500 mg of clarithromycin (CLR), 100 mg of fluconazole (FCZ), or 150 mg of rifabutin (RFB). The CLR study was conducted with 24 subjects. The geometric mean ratios (GMR) and 90% confidence intervals (90% CI; given in parentheses) of the areas under the concentration-time curve (AUC), the maximum concentrations of the drugs in serum (C(max)), and the concentrations in serum at 12 h postdose (Cp12h) for multiple-dose TPV/r and multiple-dose CLR, indicating the effect of TPV/r on the CLR parameters, were 1.19 (1.04-1.37), 0.95 (0.83-1.09), and 1.68 (1.42-1.98), respectively. The formation of the metabolite 14-OH-CLR was decreased by 95% in the presence of TPV, and the TPV AUC increased 66% compared to that for human immunodeficiency virus (HIV)-negative historical controls. The FCZ study was conducted with 20 subjects. The GMR (and 90% CI) of the AUC, C(max), and Cp24h, indicating the effect of multiple-dose TPV/r on the multiple-dose FCZ parameters, were 0.92 (0.88-0.95), 0.94 (0.91-0.98), and 0.89 (0.85-0.92), respectively. The TPV AUC increased by 50% compared to that for HIV-negative historical controls. The RFB study was conducted with 24 subjects. The GMR (and 90% CI) of the AUC, C(max), and Cp12h for multiple-dose TPV/r and single-dose RFB, indicating the effect of TPV/r on the RFB parameters, were 2.90 (2.59-3.26), 1.70 (1.49-1.94), and 2.14 (1.90-2.41), respectively. The GMR (and 90% CI) of the AUC, C(max), and Cp12h of TPV/r and RFB with 25-O-desacetyl-RFB were 4.33 (3.86-4.86), 1.86 (1.63-2.12), and 2.76 (2.44-3.12), respectively. Coadministration of TPV with a single dose of RFB resulted in a 16% increase in the TPV Cp12h compared to that for TPV alone. In the general population, no dose adjustments are necessary for the combination of TPV/r and CLR or FCZ. Combining TPV/r with RFB should be done with caution, while toxicity and RFB drug levels should be monitored. Study medications were generally well-tolerated in these studies.
- Published
- 2009
- Full Text
- View/download PDF
21. Combined tipranavir and enfuvirtide use associated with higher plasma tipranavir concentrations but not with increased hepatotoxicity: sub-analysis from RESIST.
- Author
-
Raffi F, Battegay M, Rusconi S, Opravil M, Blick G, Steigbigel RT, Kraft M, Neubacher D, and Sabo JP
- Subjects
- Alanine Transaminase blood, Drug Therapy, Combination, Enfuvirtide, HIV Fusion Inhibitors therapeutic use, HIV Infections blood, HIV Infections enzymology, HIV Protease Inhibitors therapeutic use, Humans, Liver Diseases enzymology, Lopinavir, Pyridines blood, Pyrimidinones therapeutic use, Pyrones blood, Randomized Controlled Trials as Topic, Ritonavir therapeutic use, Saquinavir therapeutic use, Sulfonamides, Treatment Outcome, Viral Load, Anti-HIV Agents therapeutic use, Chemical and Drug Induced Liver Injury, HIV Envelope Protein gp41 therapeutic use, HIV Infections drug therapy, HIV-1, Peptide Fragments therapeutic use, Pyridines therapeutic use, Pyrones therapeutic use
- Abstract
In RESIST, enfuvirtide co-administered with ritonavir-boosted tipranavir was associated with higher plasma tipranavir concentrations, which seldom rose above those associated with an increased risk of grade 3/4 transaminase elevations. Transaminase elevation rates (6.5%) and clinical hepatic event rates (5.9 events/100 person exposure years) were lower in the tipranavir/ritonavir with enfuvirtide group than in the tipranavir/ritonavir without enfuvirtide group. Observed increases in plasma tipranavir concentrations thus had no apparent effect on the risk of hepatotoxicity.
- Published
- 2007
- Full Text
- View/download PDF
22. Steady-state disposition of the nonpeptidic protease inhibitor tipranavir when coadministered with ritonavir.
- Author
-
Chen L, Sabo JP, Philip E, Mao Y, Norris SH, MacGregor TR, Wruck JM, Garfinkel S, Castles M, Brinkman A, and Valdez H
- Subjects
- Administration, Oral, Anti-HIV Agents administration & dosage, Anti-HIV Agents adverse effects, Anti-HIV Agents blood, Anti-HIV Agents metabolism, Anti-HIV Agents urine, Capsules, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Synergism, Feces chemistry, HIV Protease Inhibitors administration & dosage, HIV Protease Inhibitors adverse effects, HIV Protease Inhibitors blood, HIV Protease Inhibitors metabolism, HIV Protease Inhibitors urine, Humans, Male, Pyridines administration & dosage, Pyridines adverse effects, Pyridines blood, Pyridines metabolism, Pyridines urine, Pyrones administration & dosage, Pyrones adverse effects, Pyrones blood, Pyrones metabolism, Pyrones urine, Ritonavir administration & dosage, Ritonavir adverse effects, Ritonavir blood, Ritonavir metabolism, Ritonavir urine, Sulfonamides, Anti-HIV Agents pharmacokinetics, HIV Protease Inhibitors pharmacokinetics, Pyridines pharmacokinetics, Pyrones pharmacokinetics, Ritonavir pharmacokinetics
- Abstract
The pharmacokinetic and metabolite profiles of the antiretroviral agent tipranavir (TPV), administered with ritonavir (RTV), in nine healthy male volunteers were characterized. Subjects received 500-mg TPV capsules with 200-mg RTV capsules twice daily for 6 days. They then received a single oral dose of 551 mg of TPV containing 90 microCi of [(14)C]TPV with 200 mg of RTV on day 7, followed by twice-daily doses of unlabeled 500-mg TPV with 200 mg of RTV for up to 20 days. Blood, urine, and feces were collected for mass balance and metabolite profiling. Metabolite profiling and identification was performed using a flow scintillation analyzer in conjunction with liquid chromatography-tandem mass spectrometry. The median recovery of radioactivity was 87.1%, with 82.3% of the total recovered radioactivity excreted in the feces and less than 5% recovered from urine. Most radioactivity was excreted within 24 to 96 h after the dose of [(14)C]TPV. Radioactivity in blood was associated primarily with plasma rather than red blood cells. Unchanged TPV accounted for 98.4 to 99.7% of plasma radioactivity. Similarly, the most common form of radioactivity excreted in feces was unchanged TPV, accounting for a mean of 79.9% of fecal radioactivity. The most abundant metabolite in feces was a hydroxyl metabolite, H-1, which accounted for 4.9% of fecal radioactivity. TPV glucuronide metabolite H-3 was the most abundant of the drug-related components in urine, corresponding to 11% of urine radioactivity. In conclusion, after the coadministration of TPV and RTV, unchanged TPV represented the primary form of circulating and excreted TPV and the primary extraction route was via the feces.
- Published
- 2007
- Full Text
- View/download PDF
23. Interaction of ritonavir-boosted tipranavir with loperamide does not result in loperamide-associated neurologic side effects in healthy volunteers.
- Author
-
Mukwaya G, MacGregor T, Hoelscher D, Heming T, Legg D, Kavanaugh K, Johnson P, Sabo JP, and McCallister S
- Subjects
- Adult, Caco-2 Cells, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Interactions, HIV Protease Inhibitors administration & dosage, HIV Protease Inhibitors adverse effects, Humans, Loperamide pharmacology, Sulfonamides, Loperamide adverse effects, Neurotoxicity Syndromes etiology, Pyridines pharmacology, Pyrones pharmacology, Ritonavir administration & dosage
- Abstract
Loperamide (LOP) is a peripherally acting opioid receptor agonist used for the management of chronic diarrhea through the reduction of gut motility. The lack of central opioid effects is partly due to the efflux activity of the multidrug resistance transporter P-glycoprotein (P-gp) at the blood-brain barrier. The protease inhibitors are substrates for P-gp and have the potential to cause increased LOP levels in the brain. Because protease inhibitors, including tipranavir (TPV), are often associated with diarrhea, they are commonly used in combination with LOP. The level of respiratory depression, the level of pupil constriction, the pharmacokinetics, and the safety of LOP alone compared with those of LOP-ritonavir (RTV), LOP-TPV, and LOP-TPV-RTV were evaluated in a randomized, open-label, parallel-group study with 24 healthy human immunodeficiency virus type 1-negative adults. Respiratory depression was assessed by determination of the ventilatory response to carbon dioxide. Tipranavir-containing regimens (LOP-TPV and LOP-TPV-RTV) caused decreases in the area under the concentration-time curve from time zero to infinity for LOP (51% and 63% decreases, respectively) and its metabolite (72% and 77% decreases, respectively), whereas RTV caused increases in the levels of exposure of LOP (121% increase) and its metabolite (44% increase). In vitro and in vivo data suggest that TPV is a substrate for and an inducer of P-gp activity. The respiratory response to LOP in combination with TPV and/or RTV was not different from that to LOP alone. There was no evidence that LOP had opioid effects in the central nervous system, as measured indirectly by CO2 response curves and pupillary response in the presence of TPV and/or RTV.
- Published
- 2005
- Full Text
- View/download PDF
24. Pharmacokinetic characterization of different dose combinations of coadministered tipranavir and ritonavir in healthy volunteers.
- Author
-
MacGregor TR, Sabo JP, Norris SH, Johnson P, Galitz L, and McCallister S
- Subjects
- Administration, Oral, Adolescent, Adult, Aged, Area Under Curve, Capsules, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Synergism, Emulsions, Female, HIV Protease Inhibitors administration & dosage, HIV Protease Inhibitors blood, Humans, Male, Middle Aged, Protein Binding drug effects, Pyridines administration & dosage, Pyridines blood, Pyrones administration & dosage, Pyrones blood, Ritonavir administration & dosage, Ritonavir blood, Sulfonamides, HIV Protease Inhibitors pharmacokinetics, Pyridines pharmacokinetics, Pyrones pharmacokinetics, Ritonavir pharmacokinetics
- Abstract
Purpose: To characterize the steady-state pharmacokinetic combination of the nonpeptidic protease inhibitor tipranavir (TPV) with ritonavir (RTV) in 95 healthy adult volunteers, a phase 1, single-center, open-label, randomized, parallel-group trial was conducted., Method: Participants received 250-mg self-emulsifying drug delivery system (SEDDS) capsules of TPV at doses between 250 mg and 1250 mg twice daily for 11 days, then received one or two RTV 100-mg SEDDS capsules, in addition to the TPV capsules, for the next 21 days., Results: Coadministration of TPV and RTV (TPV/r) resulted in a greater than 20-fold increase in steady-state TPV trough concentrations (Cssmin) as compared with TPV at steady state alone. Mean TPV Cssmin was above a preliminary target threshold of 20 microM with all but one of the RTV-boosted doses; without boosting, none of the TPV-alone doses exceeded the threshold. The average steady-state Cssmin for TPV 500 mg and 750 mg with RTV 100 mg or 200 mg were 20 to 57 times the protein-adjusted TPV IC90R49\CCR418569) for protease inhibitor-resistant HIV-1. An erythromycin breath test, a surrogate marker for cytochrome P450 isoenzyme 3A4 activity, indicated that all TPV/r combinations given provided net inhibition of this isoenzyme. The most frequent treatment-related adverse events were mild gastrointestinal symptoms., Conclusion: This phase 1 study demonstrated that RTV-boosted TPV achieves concentrations that are expected to be effective in treating drug-experienced patients.
- Published
- 2004
- Full Text
- View/download PDF
25. Pharmacokinetics of nevirapine and lamivudine in patients with HIV-1 infection.
- Author
-
Sabo JP, Lamson MJ, Leitz G, Yong CL, and MacGregor TR
- Subjects
- Adult, Age Factors, Anti-HIV Agents therapeutic use, Double-Blind Method, Drug Therapy, Combination, Female, HIV Infections drug therapy, Humans, Lamivudine therapeutic use, Male, Nevirapine therapeutic use, Nucleosides therapeutic use, Placebos, Reverse Transcriptase Inhibitors therapeutic use, Sex Factors, Trimethoprim, Sulfamethoxazole Drug Combination therapeutic use, Anti-HIV Agents pharmacokinetics, HIV Infections metabolism, HIV-1, Lamivudine pharmacokinetics, Nevirapine pharmacokinetics, Reverse Transcriptase Inhibitors pharmacokinetics
- Abstract
The purpose of this parallel treatment group, double-blind, multicenter study was to characterize the pharmacokinetics of nevirapine and lamivudine when coadministered to patients with the HIV-1 infection. This pharmacokinetic interaction study was nested within a larger Phase III clinical trial conducted to characterize the safety and efficacy of coadministered nevirapine and lamivudine. One hundred HIV-1 infected patients with CD4+ lymphocyte counts < 200 cells/mm3and who were on a background of nucleoside (zidovudine [ZDV], didanosine [ddI], zalcitabine [ddC], stavudine [d4T]) therapy were randomly assigned to be treated with either nucleoside + lamivudine + nevirapine or nucleoside + lamivudine + placebo. Each patient underwent blood sampling at defined times for the purpose of determining the concentration of nevirapine in plasma and lamivudine in serum under steady-state conditions. Each patient was also monitored closely for concomitant administration of other drugs, including ZDV, ddI, ddC, d4T and cotrimoxazole. The pharmacokinetics of nevirapine and lamivudine were characterized using nonlinear mixed-effects modeling. There were no reported serious adverse events during the 40-day pharmacokinetic study. The results of the modeling analysis revealed that nevirapine had no effect on the pharmacokinetics of lamivudine. Estimates of the apparent clearance for nevirapine (CL/F = 3.3 L/hour; 95% confidence interval [CI] 2.9 to 3.7 L/hour) and lamivudine (CL/F 27.6 L/hour; 95% CI 22 to 33.2 L/hour) were consistent with the values reported in earlier trials. However, the results also showed that concomitant administration of lamivudine with cotrimoxazole resulted in a 31% reduction in the apparent clearance of lamivudine, resulting in a 43% increase in the average steady-state lamivudine serum concentrations. These results indicate that chronic concurrent administration of cotrimoxazole with lamivudine may significantly affect the steady-state pharmacokinetics of lamivudine.
- Published
- 2000
- Full Text
- View/download PDF
26. Single dose pharmacokinetics and bioavailability of nevirapine in healthy volunteers.
- Author
-
Lamson MJ, Sabo JP, MacGregor TR, Pav JW, Rowland L, Hawi A, Cappola M, and Robinson P
- Subjects
- Administration, Oral, Adult, Analysis of Variance, Anti-HIV Agents administration & dosage, Anti-HIV Agents blood, Area Under Curve, Biological Availability, Cross-Over Studies, Half-Life, Humans, Infusions, Intravenous, Intestinal Absorption, Male, Middle Aged, Nevirapine administration & dosage, Nevirapine blood, Anti-HIV Agents pharmacokinetics, Nevirapine pharmacokinetics
- Abstract
The results of two randomized, single-dose, crossover bioavailability studies are presented which describe the pharmacokinetics and oral bioavailability of nevirapine, a novel nonnucleoside antiretroviral drug. In the first study 12 healthy male volunteers received nevirapine 15 mg via short-term i.v. infusion or orally as a 50 mg tablet or reference solution (50 mg/200 mL). Following the i.v. dose, nevirapine had a low systemic clearance (Mean +/- S.D., Cl = 1.4 +/- 0.3 L/h) and a prolonged elimination phase (t(1/2beta) = 52.8 +/- 14.8 h; MRT = 81.4 +/- 22.4 h). Nevirapine absolute bioavailability was 93 +/- 9% and 91 +/- 8% for the tablet and oral solution, respectively. In the second study, 24 healthy male volunteers were administered nevirapine as a 200 mg production-line tablet or oral reference solution (200 mg/200 mL). There was no significant difference in bioavailability between the tablet and reference solution. Overall, comparison of the pharmacokinetic parameters between the 50 and 200 mg doses indicates that nevirapine is well absorbed at clinically relevant doses. The absorption profiles using deconvolution revealed no evidence of differential enzyme induction between the two doses or routes of administration following a single dose.
- Published
- 1999
- Full Text
- View/download PDF
27. Isotype choice for chimeric antibodies affects binding properties.
- Author
-
Morelock MM, Rothlein R, Bright SM, Robinson MK, Graham ET, Sabo JP, Owens R, King DJ, Norris SH, and Scher DS
- Subjects
- Animals, Antibodies, Monoclonal genetics, Antibodies, Monoclonal isolation & purification, Base Sequence, CHO Cells, Cell Adhesion Molecules immunology, Cricetinae, Enzyme-Linked Immunosorbent Assay, Humans, Immunoglobulin Fab Fragments immunology, Immunoglobulin Isotypes genetics, Immunoglobulin Isotypes isolation & purification, Intercellular Adhesion Molecule-1, Mice, Molecular Sequence Data, Oligodeoxyribonucleotides, Recombinant Fusion Proteins, Antibodies, Monoclonal immunology, Binding Sites, Antibody, Immunoglobulin Isotypes immunology
- Abstract
Construction of a series of chimeric antibodies (murine variable region and human constant region) derived from the murine antibody BIRR1, which recognizes intercellular adhesion molecule 1 (ICAM-1), has revealed differences in the relative binding abilities of the chimeric antibody to antigen. The chimeric antibodies show a ranking of their ability to compete with BIRR1 for antigen on the surface of cells with the order BIRR1 = cIgG1 (100%) > cIgG4 (30%) > cIgG2 (10%) as demonstrated by solid-phase competitive enzyme-linked immunosorbent assay. Papain digestion yielded Fab fragments that were purified to homogeneity. Competitive enzyme-linked immunosorbent assay showed that the chimeric and murine Fab binding constants were equivalent. A solution-phase binding assay (analyzed by size exclusion high performance liquid chromatography) between the intact mAbs and recombinant soluble ICAM-1 further established that the binding constants involving the Fab arms of the two antibodies were equivalent. In summary, the murine and chimeric anti-ICAM-1 antibodies bind cellular ICAM-1 with equivalent affinities but with differing avidities.
- Published
- 1994
28. BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine.
- Author
-
Richman D, Rosenthal AS, Skoog M, Eckner RJ, Chou TC, Sabo JP, and Merluzzi VJ
- Subjects
- Antigens, Viral immunology, Cytopathogenic Effect, Viral drug effects, Drug Resistance, Microbial, Drug Synergism, HIV-2 drug effects, HeLa Cells drug effects, Humans, Macrophages drug effects, Nevirapine, Picornaviridae drug effects, Reverse Transcriptase Inhibitors, T-Lymphocytes drug effects, Viral Plaque Assay, Antiviral Agents pharmacology, HIV-1 drug effects, Pyridines pharmacology, Zidovudine pharmacology
- Abstract
A series of dipyridodiazepinones have been shown to be potent inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase. The lead compound, BI-RG-587, had a 50% inhibitory concentration of 84 nM against HIV-1 reverse transcriptase activity. This compound reduced plaque formation of HIV-1 in HeLa cells expressing the CD4 receptor by 50% at 15 nM. BI-RG-587 at comparable concentrations inhibited the production of p24 antigen following the acute infection of CEM T-lymphoblastoid cells or primary human monocyte-derived macrophages with HIV-1. No inhibitory effects against HIV-2 or against three picornaviruses were detected. Zidovudine (3'-azido-3'-deoxythymidine [AZT])-susceptible and AZT-resistant isolates of HIV-1 were equally susceptible to BI-RG-587. AZT and BI-RG-587 exhibited synergistic inhibition of HIV-1BRU at all concentrations examined.
- Published
- 1991
- Full Text
- View/download PDF
29. Effects of the Clara cell toxin, 4-ipomeanol, on pulmonary function in rats.
- Author
-
Sabo JP, Kimmel EC, and Diamond L
- Subjects
- Animals, Female, Rats, Inbred Strains, Respiratory Function Tests, Terpenes toxicity, Lung drug effects, Rats physiology, Terpenes pharmacology
- Abstract
The naturally occurring compound, 4-ipomeanol (IPO, 1-[3-furyl]-4-hydroxy-1-pentanone), selectively damages the nonciliated epithelial (Clara) cells of the terminal bronchioles. Because information is not available concerning functional changes in IPO-treated lungs, an investigation was undertaken to evaluate the in vivo pulmonary ventilatory, mechanical, and gas exchange functions of female Long-Evans rats 24 h after treatment with a single intraperitoneal dose of 1 or 5 mg IPO/kg body wt. A preliminary toxicity study established the 24-h LD50 for intraperitoneally administered IPO at 19 +/- 3 (SD) mg/kg. Significant increases in lung fluid occurred in animals treated with 15 mg IPO/kg, and histological evidence of pulmonary edema was observed in animals treated with 10 mg IPO/kg. Treatment of rats with 5 mg IPO/kg caused a significant decrease in tidal volume and a significant increase in respiratory rate and functional residual capacity-to-total lung capacity ratio (%). In rats treated with 1 mg IPO/kg, pulmonary functions were minimally affected. The functional changes observed in IPO-treated animals can be attributed to swelling and possible dysfunction of Clara cells, with subsequent alveolar interstitial edema and stimulation of juxtapulmonary capillary receptors, or to a direct effect of the toxin on respiratory control mechanisms.
- Published
- 1983
- Full Text
- View/download PDF
30. The effect of selected drugs on first-stage radioemesis in beagle dogs.
- Author
-
Gralla EJ, Sabo JP, Hayden DW, Yochmowitz MG, and Mattsson JL
- Subjects
- Amifostine administration & dosage, Amphetamine administration & dosage, Animals, Body Weight, Chlorpromazine administration & dosage, Dimenhydrinate administration & dosage, Diphenhydramine administration & dosage, Dogs, Drug Combinations, Perphenazine administration & dosage, Phenytoin administration & dosage, Scopolamine administration & dosage, Vomiting etiology, X-Rays, Antiemetics administration & dosage, Radiation Injuries, Experimental prevention & control, Vomiting prevention & control
- Published
- 1979
31. Acute toxicity of latex microspheres.
- Author
-
Yokel RA, Sabo JP, Simmons GH, and DeLuca PP
- Subjects
- Animals, Dyspnea chemically induced, Lethal Dose 50, Male, Particle Size, Rats, Rats, Inbred Strains, Latex toxicity, Microspheres
- Abstract
The distribution and acute lethality of i.v. administered 3 micrometers latex spheres were determined in rats. The results extend previous studies demonstrating the similarity between dog and rat in the dynamics of microspheres in these species and the inverse relationship between sphere diameter and hemodynamic toxicity. The results suggest that 3 micrometers spheres may be safe imaging agents or drug delivery systems for spleen and liver when administered slowly. Acute hemodynamic toxicity appears to be a function of the total volume of the spheres injected.
- Published
- 1981
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.